Back to Results
First PageMeta Content
Business / Human resource management / Mergers and acquisitions / Alkermes


Ruthigen and Pulmatrix Enter into Merger Agreement Santa Rosa, Ca., March --- March 16, 2015 – Ruthigen, Inc. (NASDAQ: RTGN) (“Ruthigen”), and Pulmatrix, Inc., (“Pulmatrix”), a Lexington, Massachusetts based cl
Add to Reading List

Document Date: 2015-03-15 17:16:41

Open Document

File Size: 92,67 KB

Share Result on Facebook

City

Lexington / Santa Rosa / /

Company

Merck & Co. / Johnson & Johnson / Pearl Therapeutics / 5AM Ventures / Amgen / Cubist Pharmaceuticals / Advanced Inhalation Research Inc. / Decode Genetics / Pulmatrix Inc. / Alkermes Inc. / Dawson James Securities Inc. / Ruthigen Inc. / Transform Pharmaceuticals / Polaris Partners / Pulmatrix Enter / Inspire Pharmaceuticals / Palladium Capital Advisors LLC / AstraZeneca / NASDAQ Capital Market / /

Currency

USD / /

Event

Employment Change / M&A / Name Change / Funding / FDA Phase / /

IndustryTerm

stage biotechnology / dry powder inhaler technologies / biopharmaceutical / invasive applications / treatment of cystic fibrosis / therapeutic products / iSPERSE technology / developed using Pulmatrix’s iSPERSE technology / /

MedicalCondition

cystic fibrosis / chronic obstructive pulmonary disease / infection / respiratory disease / /

Organization

Pulmatrix's mission / U.S. Securities and Exchange Commission / /

Person

Terry McGuire / Sameer Harish / Robert Clarke / Hoji Alimi / Scott Rocklage / /

/

Position

agent and financial advisor / advisor / board member / managing partner / Director of Life Sciences / CEO and Chairman / President and Chief Executive Officer / Chairman & CEO / senior board member / former Chairman & CEO / co-founder / /

Product

PUR0200 / Pulmatrix / /

ProvinceOrState

Massachusetts / /

Technology

dry powder inhaler technologies / iSPERSE technology / biotechnology / drug delivery / drug development / /

URL

http /

SocialTag